522 related articles for article (PubMed ID: 15217936)
1. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.
Maquoi E; Sounni NE; Devy L; Olivier F; Frankenne F; Krell HW; Grams F; Foidart JM; Noël A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4038-47. PubMed ID: 15217936
[TBL] [Abstract][Full Text] [Related]
2. The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model.
Lein M; Jung K; Ortel B; Stephan C; Rothaug W; Juchem R; Johannsen M; Deger S; Schnorr D; Loening S; Krell HW
Oncogene; 2002 Mar; 21(13):2089-96. PubMed ID: 11960381
[TBL] [Abstract][Full Text] [Related]
3. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
Zucker S; Cao J; Chen WT
Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
[TBL] [Abstract][Full Text] [Related]
4. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
Della Porta P; Soeltl R; Krell HW; Collins K; O'Donoghue M; Schmitt M; Krüger A
Anticancer Res; 1999; 19(5B):3809-16. PubMed ID: 10628317
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of a novel matrix metalloproteinase inhibitor on pancreatic adenocarcinoma cells in vitro and in an orthotopic pancreatic cancer model in vivo.
Kapischke M; Fischer T; Tiessen K; Tschesche H; Bruch HP; Kalthoff H; Kruse ML
Int J Oncol; 2008 Jan; 32(1):273-82. PubMed ID: 18097568
[TBL] [Abstract][Full Text] [Related]
6. [Antiangiogenic and antitumor effect of BPHA, an orally-active matrix metalloproteinase inhibitor, in in vivo murine and human tumor model].
Maki H; Maekawa R; Yoshida H; Hojo K; Uchida N; Wada T; Tanaka H; Takeda Y; Matsumoto M; Yamada H; Nishitani Y; Shono K; Kasai H; Sato S; Okamoto H; Hayashi R; Tamura Y; Tsuzuki H; Watanabe F; Sugita K; Yoshioka T
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1599-606. PubMed ID: 10553417
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase inhibition suppresses MMP-2 activity and activation of PANC-1 cells in vitro.
Zervos EE; Shafii AE; Haq M; Rosemurgy AS
J Surg Res; 1999 Jun; 84(2):162-7. PubMed ID: 10357914
[TBL] [Abstract][Full Text] [Related]
8. A novel matrix metalloproteinase inhibitor, FYK-1388 suppresses tumor growth, metastasis and angiogenesis by human fibrosarcoma cell line.
Shinoda K; Shibuya M; Hibino S; Ono Y; Matsuda K; Takemura A; Zou D; Kokubo Y; Takechi A; Kudoh S
Int J Oncol; 2003 Feb; 22(2):281-8. PubMed ID: 12527923
[TBL] [Abstract][Full Text] [Related]
9. Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation.
Augé N; Maupas-Schwalm F; Elbaz M; Thiers JC; Waysbort A; Itohara S; Krell HW; Salvayre R; Nègre-Salvayre A
Circulation; 2004 Aug; 110(5):571-8. PubMed ID: 15277330
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer.
Zervos EE; Shafii AE; Rosemurgy AS
J Surg Res; 1999 Jan; 81(1):65-8. PubMed ID: 9889060
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of a benz[f]indole-4,9-dione analog on cancer cell metastasis mediated by the down-regulation of matrix metalloproteinase expression in human HT1080 fibrosarcoma cells.
Park HJ; Lee HJ; Min HY; Chung HJ; Suh ME; Park-Choo HY; Kim C; Kim HJ; Seo EK; Lee SK
Eur J Pharmacol; 2005 Dec; 527(1-3):31-6. PubMed ID: 16309669
[TBL] [Abstract][Full Text] [Related]
13. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor.
Maekawa R; Maki H; Yoshida H; Hojo K; Tanaka H; Wada T; Uchida N; Takeda Y; Kasai H; Okamoto H; Tsuzuki H; Kambayashi Y; Watanabe F; Kawada K; Toda K; Ohtani M; Sugita K; Yoshioka T
Cancer Res; 1999 Mar; 59(6):1231-5. PubMed ID: 10096553
[TBL] [Abstract][Full Text] [Related]
14. Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model.
Abramjuk C; Lein M; Rothaug W; Krell HW; Loening SA; Jung K
Cancer Chemother Pharmacol; 2007 Feb; 59(2):275-82. PubMed ID: 16758188
[TBL] [Abstract][Full Text] [Related]
15. Stimulation of matrix metalloproteinase-9 expression in human fibrosarcoma cells by synthetic matrix metalloproteinase inhibitors.
Maquoi E; Munaut C; Colige A; Lambert C; Frankenne F; Noël A; Grams F; Krell HW; Foidart JM
Exp Cell Res; 2002 Apr; 275(1):110-21. PubMed ID: 11925109
[TBL] [Abstract][Full Text] [Related]
16. Functional role of matrix metalloproteinases (MMPs) in mammary epithelial cell development.
Lee PP; Hwang JJ; Mead L; Ip MM
J Cell Physiol; 2001 Jul; 188(1):75-88. PubMed ID: 11382924
[TBL] [Abstract][Full Text] [Related]
17. Galloyl cyclic-imide derivative CH1104I inhibits tumor invasion through suppressing matrix metalloproteinase activity.
Chen MH; Cui SX; Cheng YN; Sun LR; Li QB; Xu WF; Ward SG; Tang W; Qu XJ
Anticancer Drugs; 2008 Nov; 19(10):957-65. PubMed ID: 18827560
[TBL] [Abstract][Full Text] [Related]
18. Increase in tissue inhibitor of metalloproteinase-2 (TIMP-2) levels and inhibition of MMP-2 activity in a metastatic breast cancer cell line by an anti-invasive small molecule SR13179.
Waleh NS; Murphy BJ; Zaveri NT
Cancer Lett; 2010 Mar; 289(1):111-8. PubMed ID: 19751965
[TBL] [Abstract][Full Text] [Related]
19. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice.
Low JA; Johnson MD; Bone EA; Dickson RB
Clin Cancer Res; 1996 Jul; 2(7):1207-14. PubMed ID: 9816289
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies.
Folgueras AR; Pendás AM; Sánchez LM; López-Otín C
Int J Dev Biol; 2004; 48(5-6):411-24. PubMed ID: 15349816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
